Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic Expands Minimally Invasive Surgery Line With AF, Valve Products

This article was originally published in The Gray Sheet

Executive Summary

Medtronic is developing a clinical trial for a minimally invasive ablation device for non-concomitant treatment of atrial fibrillation, or lone AF

You may also be interested in...

Canadian Study Prompts Edwards To Rethink PVT Feasibility Trial

Edwards Lifesciences intends to resume a U.S. PVT percutaneous aortic valve feasibility trial by year-end

CoreValve Expands Percutaneous Aortic Valve Trial In Europe

CoreValve plans to begin a 250-patient European pivotal trial of its ReValving self-expanding percutaneous aortic valve replacement system by year-end

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts